The tweet was deleted by the author.
But we saved everything 🙂.
CVRx launches THT2026 today, featuring a comprehensive program of scientific presentations focused on Barostim.
Attendees will gain insight from late-breaking clinical data, oral sessions, and research posters that emphasize real-world outcomes, advances in cardiac energetics, and broader impacts of Barostim therapy. The event is positioned as a central forum for researchers and clinicians to examine the latest evidence in device-based modulation of cardiovascular function.